https://ir.sutrobio.com/ https://ir.sutrobio.com/press-releases https://ir.sutrobio.com/events-presentations https://ir.sutrobio.com/financials/financial-results https://ir.sutrobio.com/financials/sec-filings https://ir.sutrobio.com/financials/annual-reports https://ir.sutrobio.com/stock-data/quote-chart https://ir.sutrobio.com/stock-data/historical-data https://ir.sutrobio.com/stock-data/analyst-coverage https://ir.sutrobio.com/governance https://ir.sutrobio.com/governance/board-committees https://ir.sutrobio.com/governance/governance-documents https://ir.sutrobio.com/ir-resources/faq https://ir.sutrobio.com/ir-resources/email-alerts https://ir.sutrobio.com/ir-resources/contact https://ir.sutrobio.com/press-releases/detail/231/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights 2026-03-23T16:05:02-04:00 https://ir.sutrobio.com/press-releases/detail/230/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2026-02-25T08:30:03-05:00 https://ir.sutrobio.com/press-releases/detail/229/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit 2026-02-23T08:30:01-05:00 https://ir.sutrobio.com/press-releases/detail/228/sutro-biopharma-announces-pricing-of-110-0-million-underwritten-offering 2026-02-10T07:00:03-05:00 https://ir.sutrobio.com/press-releases/detail/227/sutro-biopharma-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference 2026-01-07T16:05:03-05:00 https://ir.sutrobio.com/press-releases/detail/226/sutro-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2025-12-17T16:05:02-05:00 https://ir.sutrobio.com/press-releases/detail/225/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2025-12-16T16:05:02-05:00 https://ir.sutrobio.com/press-releases/detail/224/sutro-biopharma-announces-first-cohort-of-patients-dosed-in-phase-1-trial-of-stro-004-a-next-generation-tissue-factor-adc-in-tf-expressing-solid-tumors 2025-12-03T08:00:04-05:00 https://ir.sutrobio.com/press-releases/detail/223/sutro-biopharma-announces-1-for-10-reverse-stock-split 2025-12-01T08:00:01-05:00 https://ir.sutrobio.com/press-releases/detail/222/sutro-biopharma-highlights-next-generation-adc-innovation-at-virtual-rd-day 2025-11-12T10:00:01-05:00 https://ir.sutrobio.com/press-releases/detail/221/sutro-biopharma-reports-third-quarter-2025-financial-results-and-business-highlights 2025-11-06T16:30:15-05:00 https://ir.sutrobio.com/press-releases/detail/220/sutro-biopharma-to-host-virtual-research-development-day-on-november-12-2025 2025-11-05T16:05:19-05:00 https://ir.sutrobio.com/press-releases/detail/219/sutro-biopharma-announces-participation-at-the-16th-annual-world-adc-conference 2025-11-03T08:01:08-05:00 https://ir.sutrobio.com/press-releases/detail/218/sutro-biopharma-announces-operational-restructuring-intended-to-extend-cash-runway-through-key-milestones 2025-09-29T17:05:17-04:00 https://ir.sutrobio.com/press-releases/detail/217/sutro-biopharma-reports-second-quarter-2025-financial-results-and-business-highlights 2025-08-07T16:30:06-04:00 https://ir.sutrobio.com/press-releases/detail/216/sutro-biopharma-announces-research-collaboration-with-the-fda-to-advance-regulatory-standards-for-antibody-drug-conjugates 2025-07-22T08:00:14-04:00 https://ir.sutrobio.com/press-releases/detail/215/sutro-biopharma-appoints-greg-chow-as-chief-financial-officer 2025-06-02T08:00:07-04:00 https://ir.sutrobio.com/press-releases/detail/214/sutro-biopharma-reports-first-quarter-2025-financial-results-and-business-highlights 2025-05-08T16:31:43-04:00 https://ir.sutrobio.com/press-releases/detail/213/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2025-05-01T16:05:25-04:00 https://ir.sutrobio.com/press-releases/detail/212/sutro-biopharma-to-highlight-its-next-generation-exatecan-and-dual-payload-adc-programs-in-presentations-at-aacr-2025 2025-04-28T16:05:05-04:00 https://ir.sutrobio.com/press-releases/detail/211/sutro-biopharma-presents-data-from-dose-optimization-portion-of-refrme-o1-trial-in-patients-with-platinum-resistant-ovarian-cancer-at-sgo-2025 2025-03-15T18:40:01-04:00 https://ir.sutrobio.com/press-releases/detail/210/sutro-biopharma-reports-full-year-2024-financial-results-and-business-highlights 2025-03-13T16:07:02-04:00 https://ir.sutrobio.com/press-releases/detail/209/sutro-biopharma-announces-strategic-portfolio-review-resulting-in-the-prioritization-of-its-next-generation-adc-pipeline 2025-03-13T16:05:29-04:00 https://ir.sutrobio.com/press-releases/detail/208/sutro-biopharma-to-present-at-the-td-cowen-45th-annual-health-care-conference 2025-03-03T16:05:18-05:00 https://ir.sutrobio.com/press-releases/detail/207/sutro-biopharma-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T16:05:18-05:00 https://ir.sutrobio.com/press-releases/detail/206/sutro-biopharma-and-boehringer-ingelheim-bioxcellence-collaboration-established-first-in-class-cell-free-capabilities-at-commercial-scale 2025-01-07T09:00:14-05:00 https://ir.sutrobio.com/press-releases/detail/205/sutro-biopharma-announces-selected-dose-for-luvelta-and-topline-results-from-dose-optimization-portion-of-refrme-o1-trial-in-platinum-resistant-ovarian-cancer 2024-12-10T08:00:28-05:00 https://ir.sutrobio.com/press-releases/detail/204/sutro-biopharma-reports-third-quarter-2024-financial-results-and-business-highlights 2024-11-13T16:30:04-05:00 https://ir.sutrobio.com/press-releases/detail/203/sutro-biopharma-demonstrates-meaningful-adc-innovation-with-five-presentations-at-the-15th-annual-world-adc-conference 2024-11-04T16:05:02-05:00 https://ir.sutrobio.com/press-releases/detail/202/sutro-biopharma-announces-initiation-of-the-registration-enabling-refrme-p1-trial-with-luvelta-for-pediatric-patients-with-cbfglis-aml 2024-11-01T08:00:04-04:00 https://ir.sutrobio.com/press-releases/detail/201/sutro-biopharma-highlights-next-generation-adc-innovation-and-near-term-pipeline-at-research-forum 2024-10-10T16:05:01-04:00 https://ir.sutrobio.com/press-releases/detail/200/sutro-biopharma-announces-inducement-grant-under-nasdaq-listing-rule-5635c4 2024-09-20T16:01:01-04:00 https://ir.sutrobio.com/press-releases/detail/199/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination-with-bevacizumab-at-esmo-2024 2024-09-14T03:00:04-04:00 https://ir.sutrobio.com/press-releases/detail/198/sutro-biopharma-to-host-research-forum-highlighting-next-generation-adc-innovation-and-near-term-pipeline-on-october-10-2024 2024-09-11T08:00:11-04:00 https://ir.sutrobio.com/press-releases/detail/197/sutro-biopharma-announces-initiation-of-refrme-l1-phase-2-trial-with-luvelta-for-patients-with-non-small-cell-lung-cancer 2024-08-22T08:00:02-04:00 https://ir.sutrobio.com/press-releases/detail/196/sutro-biopharma-reports-second-quarter-2024-financial-results-business-highlights-and-select-anticipated-milestones 2024-08-13T16:30:02-04:00 https://ir.sutrobio.com/press-releases/detail/195/sutro-biopharma-appoints-dr-barbara-leyman-as-chief-business-development-officer 2024-07-09T08:00:07-04:00 https://ir.sutrobio.com/press-releases/detail/194/sutro-biopharma-reports-first-quarter-2024-financial-results-business-highlights-and-select-anticipated-milestones 2024-05-13T16:30:01-04:00 https://ir.sutrobio.com/press-releases/detail/193/sutro-biopharma-announces-initiation-of-randomized-portion-part-2-of-refrme-o1-trial 2024-04-30T08:00:07-04:00 https://ir.sutrobio.com/press-releases/detail/192/sutro-biopharma-announces-pricing-of-75-million-underwritten-offering 2024-04-02T06:18:57-04:00 https://ir.sutrobio.com/press-releases/detail/191/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeting-solid-tumors 2024-04-02T01:14:58-04:00 https://ir.sutrobio.com/press-releases/detail/190/sutro-biopharma-reports-full-year-2023-financial-results-business-highlights-and-select-anticipated-milestones 2024-03-25T16:30:01-04:00 https://ir.sutrobio.com/press-releases/detail/189/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2024-02-06T16:05:12-05:00 https://ir.sutrobio.com/press-releases/detail/188/sutro-biopharma-highlights-potential-multi-cancer-opportunity-for-luvelta-a-folr-targeting-adc 2024-01-04T16:05:02-05:00 https://ir.sutrobio.com/press-releases/detail/187/sutro-biopharma-to-host-investor-webcast-highlighting-potential-multi-cancer-opportunity-for-luvelta-a-folr-targeted-adc-on-january-4-2024 2023-12-14T16:05:01-05:00 https://ir.sutrobio.com/press-releases/detail/186/sutro-biopharma-announces-new-positive-data-from-the-compassionate-use-of-luveltamab-tazevibulin-luvelta-in-pediatric-patients-with-relapsedrefractory-cbfglis-presented-at-ash-2023 2023-12-11T16:05:01-05:00 https://ir.sutrobio.com/press-releases/detail/185/sutro-biopharma-to-participate-in-the-jmp-securities-hematology-and-oncology-summit 2023-12-04T16:05:05-05:00 https://ir.sutrobio.com/press-releases/detail/184/vaxcyte-exercises-option-and-enters-into-manufacturing-rights-agreement-with-sutro-biopharma-to-obtain-control-over-manufacturing-and-development-of-cell-free-extract-for-its-vaccine-candidates 2023-11-27T16:24:48-05:00 https://ir.sutrobio.com/press-releases/detail/183/sutro-biopharma-promotes-jane-chung-to-president-and-chief-operating-officer 2023-11-21T16:05:02-05:00 https://ir.sutrobio.com/press-releases/detail/182/sutro-biopharma-reports-third-quarter-2023-financial-results-business-highlights-and-select-anticipated-milestones 2023-11-13T16:30:08-05:00 https://ir.sutrobio.com/press-releases/detail/181/sutro-biopharma-announces-presentation-of-data-for-luveltamab-tazevibulin-luvelta-from-the-phase-1-dose-expansion-study-in-endometrial-cancers-at-esmo-2023 2023-10-22T04:25:01-04:00 https://ir.sutrobio.com/press-releases/detail/180/sutro-demonstrates-meaningful-adc-innovation-with-five-presentations-and-one-poster-at-the-14th-annual-world-adc-conference 2023-10-16T16:05:02-04:00 https://ir.sutrobio.com/press-releases/detail/179/sutro-biopharma-appoints-dr-hans-peter-gerber-as-chief-scientific-officer 2023-09-19T08:00:03-04:00 https://ir.sutrobio.com/press-releases/detail/178/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2023-08-30T08:00:01-04:00 https://ir.sutrobio.com/press-releases/detail/177/sutro-biopharma-reports-second-quarter-2023-financial-results-business-highlights-and-select-anticipated-milestones 2023-08-10T16:30:02-04:00 https://ir.sutrobio.com/press-releases/detail/176/sutro-biopharma-and-blackstone-announce-royalty-financing-collaboration 2023-06-26T08:00:06-04:00 https://ir.sutrobio.com/press-releases/detail/175/sutro-biopharma-announces-oral-presentation-at-asco-2023-featuring-data-for-luveltamab-tazevibulin-from-the-phase-1-dose-expansion-study-in-ovarian-cancer-and-the-initiation-of-the-phase-23-pivotal-study-reframe-o1 2023-06-03T16:00:01-04:00 https://ir.sutrobio.com/press-releases/detail/174/sutro-biopharma-to-participate-in-the-jefferies-healthcare-conference 2023-05-31T08:00:03-04:00 https://ir.sutrobio.com/press-releases/detail/173/sutro-biopharma-reports-first-quarter-2023-financial-results-business-highlights-and-select-anticipated-milestones 2023-05-15T08:00:03-04:00 https://ir.sutrobio.com/press-releases/detail/172/sutro-biopharma-to-present-at-the-jmp-securities-life-sciences-conference 2023-05-08T08:00:07-04:00 https://ir.sutrobio.com/press-releases/detail/171/sutro-biopharma-announces-the-departure-of-president-of-research-chief-scientific-officer 2023-04-27T16:30:20-04:00 https://ir.sutrobio.com/press-releases/detail/170/sutro-biopharma-presents-preclinical-data-for-its-ror1-targeting-antibody-drug-conjugate-stro-003-at-the-aacr-annual-meeting-2023 2023-04-18T13:30:02-04:00 https://ir.sutrobio.com/press-releases/detail/169/sutro-biopharma-reports-full-year-2022-financial-results-business-highlights-and-select-anticipated-milestones 2023-03-30T16:30:03-04:00 https://ir.sutrobio.com/press-releases/detail/168/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2023-03-17T16:01:02-04:00 https://ir.sutrobio.com/press-releases/detail/167/sutro-biopharma-to-present-at-the-cowen-43rd-annual-health-care-conference 2023-03-01T08:00:15-05:00 https://ir.sutrobio.com/press-releases/detail/166/sutro-biopharma-appoints-dr-anne-borgman-as-chief-medical-officer 2023-02-28T08:00:13-05:00 https://ir.sutrobio.com/press-releases/detail/165/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2023-02-17T16:01:01-05:00 https://ir.sutrobio.com/press-releases/detail/164/sutro-biopharma-announces-update-from-stro-002-luveltamab-tazevibulin-luvelta-phase-1-dose-expansion-study-and-registrational-plans-in-advanced-ovarian-cancer 2023-01-09T16:05:01-05:00 https://ir.sutrobio.com/press-releases/detail/163/sutro-biopharma-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference 2023-01-04T08:00:04-05:00 https://ir.sutrobio.com/press-releases/detail/162/sutro-biopharma-to-provide-data-update-on-stro-002-and-plans-for-registrational-path-forward-in-advanced-ovarian-cancer 2022-12-21T08:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/161/sutro-biopharma-and-vaxcyte-enter-into-option-grant-agreement-for-the-development-and-manufacturing-rights-of-cell-free-extract 2022-12-20T16:05:05-05:00 https://ir.sutrobio.com/press-releases/detail/160/sutro-biopharma-announces-presentation-of-stro-002-data-from-the-compassionate-use-program-in-pediatric-patients-with-relapsedrefractory-cbfglis-aml-at-ash-2022 2022-12-10T10:30:01-05:00 https://ir.sutrobio.com/press-releases/detail/159/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2022-11-23T07:00:03-05:00 https://ir.sutrobio.com/press-releases/detail/158/sutro-biopharma-reports-third-quarter-2022-financial-results-business-highlights-and-select-anticipated-milestones 2022-11-08T16:30:05-05:00 https://ir.sutrobio.com/press-releases/detail/157/sutro-biopharma-announces-oral-presentation-at-the-64th-american-society-of-hematology-annual-meeting-and-exposition 2022-11-03T09:00:15-04:00 https://ir.sutrobio.com/press-releases/detail/156/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2022-11-02T07:00:05-04:00 https://ir.sutrobio.com/press-releases/detail/155/sutro-biopharma-announces-departure-of-chief-medical-officer 2022-10-24T07:00:08-04:00 https://ir.sutrobio.com/press-releases/detail/154/sutro-biopharma-to-present-at-the-2022-wells-fargo-healthcare-conference 2022-09-01T07:00:04-04:00 https://ir.sutrobio.com/press-releases/detail/153/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-08-19T16:01:02-04:00 https://ir.sutrobio.com/press-releases/detail/152/sutro-biopharma-reports-second-quarter-2022-financial-results-business-highlights-and-anticipated-milestones 2022-08-08T16:30:04-04:00 https://ir.sutrobio.com/press-releases/detail/151/sutro-biopharma-to-present-at-the-2022-wedbush-pacgrow-healthcare-conference 2022-08-03T07:00:09-04:00 https://ir.sutrobio.com/press-releases/detail/150/sutro-biopharma-achieves-first-in-human-milestone-in-cytokine-derivatives-collaboration-with-merck 2022-07-26T16:01:01-04:00 https://ir.sutrobio.com/press-releases/detail/149/sutro-biopharma-announces-virtual-deep-dive-research-forum-next-gen-innovations-in-adcs 2022-07-12T07:00:03-04:00 https://ir.sutrobio.com/press-releases/detail/148/astellas-and-sutro-biopharmaannounce-worldwide-strategic-collaboration-to-advance-novel-immunostimulatory-antibody-drug-conjugates-iadcs 2022-06-27T19:31:01-04:00 https://ir.sutrobio.com/press-releases/detail/147/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-06-08T08:34:19-04:00 https://ir.sutrobio.com/press-releases/detail/146/sutro-biopharma-to-participate-in-upcoming-investor-conferences 2022-06-02T07:00:09-04:00 https://ir.sutrobio.com/press-releases/detail/145/sutro-biopharma-reports-first-quarter-2022-financial-results-business-highlights-and-anticipated-milestones 2022-05-09T18:06:43-04:00 https://ir.sutrobio.com/press-releases/detail/144/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2022-04-29T17:00:04-04:00 https://ir.sutrobio.com/press-releases/detail/143/sutro-biopharma-presents-nonclinical-data-for-antibody-drug-conjugate-stro-002-at-the-aacr-annual-meeting-2022 2022-04-08T13:00:05-04:00 https://ir.sutrobio.com/press-releases/detail/142/sutro-biopharma-to-present-at-the-21st-annual-needham-virtual-healthcare-conference 2022-04-05T07:00:11-04:00 https://ir.sutrobio.com/press-releases/detail/141/sutro-biopharma-presented-on-advances-in-novel-immunostimulatory-antibody-drug-conjugate-modality-at-the-12th-annual-world-adc 2022-03-30T16:05:46-04:00 https://ir.sutrobio.com/press-releases/detail/140/sutro-biopharma-to-participate-in-the-cowen-42nd-annual-healthcare-conference 2022-03-03T07:00:16-05:00 https://ir.sutrobio.com/press-releases/detail/139/sutro-biopharma-reports-full-year-2021-financial-results-business-highlights-and-anticipated-2022-milestones 2022-02-28T16:35:04-05:00 https://ir.sutrobio.com/press-releases/detail/138/sutro-biopharma-to-present-at-the-40th-annual-j-p-morgan-virtual-healthcare-conference 2022-01-06T07:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/137/sutro-biopharma-announces-interim-data-from-dose-expansion-cohort-of-stro-002-phase-1-study-for-patients-with-advanced-ovarian-cancer 2022-01-05T16:30:08-05:00 https://ir.sutrobio.com/press-releases/detail/136/sutro-biopharma-and-tasly-biopharmaceuticals-enter-into-exclusive-license-agreement-for-stro-002-in-greater-china 2021-12-27T07:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/135/sutro-biopharma-announces-company-kol-virtual-event-to-provide-interim-dose-expansion-data-for-antibody-drug-conjugate-program-stro-002-for-treatment-of-advanced-ovarian-cancer 2021-12-27T07:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/134/fred-hutchinson-cancer-research-center-in-partnership-with-sutro-biopharma-to-present-at-ash-2021 2021-12-13T07:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/133/sutro-biopharma-to-participate-in-two-upcoming-investor-conferences 2021-11-22T07:00:09-05:00 https://ir.sutrobio.com/press-releases/detail/132/sutro-biopharma-announces-appointment-of-heidi-hunter-to-board-of-directors 2021-11-17T07:00:11-05:00 https://ir.sutrobio.com/press-releases/detail/131/sutro-biopharma-reports-third-quarter-2021-financial-results-business-highlights-and-anticipated-2021-milestones 2021-11-10T07:00:43-05:00 https://ir.sutrobio.com/press-releases/detail/130/sutro-biopharma-to-participate-in-three-upcoming-investor-conferences 2021-11-02T07:00:14-04:00 https://ir.sutrobio.com/press-releases/detail/129/sutro-biopharma-and-bionova-pharmaceuticals-enter-into-collaboration-for-stro-001-in-greater-china 2021-10-12T07:00:14-04:00 https://ir.sutrobio.com/press-releases/detail/128/sutro-biopharma-announces-extension-of-cytokine-derivative-research-program-under-collaboration-with-merck 2021-09-30T07:00:11-04:00 https://ir.sutrobio.com/press-releases/detail/127/sutro-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4 2021-09-17T17:00:04-04:00 https://ir.sutrobio.com/press-releases/detail/126/sutro-biopharma-announces-expansion-of-leadership-team 2021-09-16T07:00:09-04:00 https://ir.sutrobio.com/press-releases/detail/125/sutro-biopharma-to-participate-in-the-2021-wells-fargo-virtual-healthcare-conference 2021-09-01T07:00:12-04:00 https://ir.sutrobio.com/press-releases/detail/124/sutro-biopharma-announces-stro-002-fda-fast-track-designation-for-patients-with-advanced-ovarian-cancer 2021-08-18T07:00:28-04:00 https://ir.sutrobio.com/press-releases/detail/123/sutro-biopharma-reports-second-quarter-2021-financial-results-business-highlights-and-anticipated-second-half-2021-milestones 2021-08-09T07:05:04-04:00 https://ir.sutrobio.com/press-releases/detail/122/sutro-biopharma-appoints-jane-chung-as-chief-commercial-officer 2021-08-09T07:00:13-04:00 https://ir.sutrobio.com/press-releases/detail/121/sutro-biopharma-to-participate-in-the-12th-annual-wedbush-pacgrow-healthcare-virtual-conference 2021-07-29T07:00:34-04:00 https://ir.sutrobio.com/press-releases/detail/120/sutro-biopharma-to-participate-in-two-virtual-investor-conferences-in-june 2021-06-15T07:10:10-04:00 https://ir.sutrobio.com/press-releases/detail/119/sutro-biopharma-earns-milestone-payment-from-bispecific-antibody-drug-conjugate-collaboration-with-merck-kgaa-darmstadt-germany 2021-06-01T07:00:21-04:00 https://ir.sutrobio.com/press-releases/detail/118/sutro-biopharma-announces-additional-data-for-dose-escalation-phase-1-study-of-stro-002-to-be-presented-at-asco-2021 2021-05-19T17:00:12-04:00 https://ir.sutrobio.com/press-releases/detail/117/sutro-biopharma-to-participate-in-upcoming-virtual-investor-conferences 2021-05-14T07:00:07-04:00 https://ir.sutrobio.com/press-releases/detail/116/sutro-biopharma-reports-first-quarter-2021-financial-results-business-highlights-and-2021-anticipated-milestones 2021-05-07T07:00:14-04:00 https://ir.sutrobio.com/press-releases/detail/115/sutro-biopharma-promotes-trevor-hallam-ph-d-to-president-of-research-and-chief-scientific-officer 2021-04-20T07:00:11-04:00 https://ir.sutrobio.com/press-releases/detail/114/sutro-biopharma-earns-milestone-payment-from-cytokine-derivatives-collaboration-with-merck 2021-04-15T07:00:12-04:00 https://ir.sutrobio.com/press-releases/detail/113/sutro-biopharma-to-present-at-two-upcoming-investor-conferences 2021-04-08T07:00:13-04:00 https://ir.sutrobio.com/press-releases/detail/112/sutro-biopharma-strengthens-leadership-through-management-promotions-and-expansion-of-clinical-advisory-board 2021-03-22T07:00:10-04:00 https://ir.sutrobio.com/press-releases/detail/111/sutro-biopharma-reports-full-year-2020-financial-results-and-provides-business-highlights-and-2021-anticipated-milestones 2021-03-18T07:00:14-04:00 https://ir.sutrobio.com/press-releases/detail/110/sutro-biopharma-to-participate-in-the-cowen-41st-annual-healthcare-conference 2021-02-23T07:00:20-05:00 https://ir.sutrobio.com/press-releases/detail/109/sutro-biopharma-announces-first-patient-dosed-in-the-dose-expansion-study-of-stro-002-in-patients-with-ovarian-cancer 2021-01-21T07:00:09-05:00 https://ir.sutrobio.com/press-releases/detail/108/sutro-biopharma-to-present-at-the-39th-annual-j-p-morgan-virtual-healthcare-conference 2021-01-05T07:00:32-05:00 https://ir.sutrobio.com/press-releases/detail/107/sutro-biopharma-announces-closing-of-upsized-144-9-million-public-offering-including-full-exercise-of-the-underwriters-option-to-purchase-additional-shares 2020-12-11T16:01:03-05:00 https://ir.sutrobio.com/press-releases/detail/106/sutro-biopharma-announces-pricing-of-126-0-million-public-offering 2020-12-08T21:10:13-05:00 https://ir.sutrobio.com/press-releases/detail/105/sutro-biopharma-announces-proposed-public-offering-of-5-million-shares-of-common-stock 2020-12-07T16:00:03-05:00 https://ir.sutrobio.com/press-releases/detail/104/sutro-biopharma-presents-data-from-ongoing-phase-1-dose-escalation-study-for-stro-001-for-the-treatment-of-b-cell-non-hodgkin-lymphoma-at-the-62nd-american-society-of-hematology-annual-meeting 2020-12-07T10:00:13-05:00 https://ir.sutrobio.com/press-releases/detail/103/sutro-biopharma-announces-encouraging-interim-data-on-stro-002-phase-1-dose-escalation-study-for-patients-with-ovarian-cancer 2020-12-03T16:30:03-05:00 https://ir.sutrobio.com/press-releases/detail/102/sutro-biopharma-announces-appointment-of-jon-m-wigginton-m-d-to-board-of-directors 2020-12-01T07:00:08-05:00 https://ir.sutrobio.com/press-releases/detail/101/sutro-biopharma-to-host-a-virtual-kol-event-to-provide-clinical-update-on-antibody-drug-conjugate-stro-002-in-ovarian-cancer 2020-11-24T07:00:04-05:00 https://ir.sutrobio.com/press-releases/detail/100/sutro-biopharma-announces-the-appointment-of-diana-landa-as-vice-president-of-regulatory-affairs-and-annie-chang-as-head-of-investor-relations 2020-11-18T07:00:07-05:00 https://ir.sutrobio.com/press-releases/detail/99/sutro-biopharma-to-participate-in-four-upcoming-investor-conferences 2020-11-11T07:00:13-05:00 https://ir.sutrobio.com/press-releases/detail/98/sutro-biopharma-reports-third-quarter-2020-financial-results-and-provides-business-highlights-and-developments 2020-11-05T07:00:19-05:00 https://ir.sutrobio.com/press-releases/detail/97/sutro-biopharma-named-best-new-drug-developer-at-the-7th-annual-world-adc 2020-09-21T07:00:08-04:00 https://ir.sutrobio.com/press-releases/detail/96/sutro-biopharma-presents-promising-stro-002-interim-phase-1-clinical-data-in-ovarian-cancer-at-the-2020-igcs-annual-global-meeting 2020-09-09T16:01:03-04:00 https://ir.sutrobio.com/press-releases/detail/95/sutro-biopharma-to-present-at-two-upcoming-investor-conferences 2020-09-03T07:00:08-04:00 https://ir.sutrobio.com/press-releases/detail/94/sutro-biopharma-announces-promising-stro-002-interim-phase-1-clinical-data-in-ovarian-cancer-and-presentation-at-the-2020-igcs-annual-global-meeting 2020-09-02T16:12:16-04:00 https://ir.sutrobio.com/press-releases/detail/93/sutro-biopharma-earns-clinical-supply-milestone-payment-from-merck-kgaa-darmstadt-germany-for-novel-bispecific-antibody-drug-conjugate-targeting-solid-tumors 2020-08-25T07:00:16-04:00 https://ir.sutrobio.com/press-releases/detail/5/sutro-biopharma-announces-two-executive-promotions-to-vice-president-of-quality-and-vice-president-of-manufacturing 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/6/sutro-biopharma-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/7/sutro-biopharma-reports-second-quarter-2020-financial-results-and-provides-business-highlights-and-developments 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/8/sutro-biopharma-presents-new-preclinical-data-at-2020-aacr-virtual-annual-meeting-ii-suggesting-synergy-between-its-stro-002-antibody-drug-conjugate-and-immune-checkpoint-inhibitors-resulting-in-tumor-regression-and-adaptive-anti-tumor-immunity 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/9/sutro-biopharma-to-present-new-preclinical-data-on-its-stro-002-antibody-drug-conjugate-at-the-upcoming-aacr-2020-virtual-meeting-on-june-22-2020 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/10/sutro-biopharma-expands-senior-management-with-the-additions-of-vice-president-of-clinical-development-and-vice-president-of-finance-and-controller 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/11/sutro-biopharma-adds-two-exceptional-leaders-to-advisory-boards---carlos-paya-md-phd-and-lainie-martin-md 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/12/sutro-biopharma-announces-closing-of-98-0-million-public-offering-including-full-exercise-of-the-underwriters-option-to-purchase-additional-shares 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/13/sutro-biopharma-announces-pricing-of-85-3-million-public-offering 2020-08-14T18:28:28-04:00 https://ir.sutrobio.com/press-releases/detail/14/sutro-biopharma-reports-first-quarter-2020-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/15/sutro-biopharma-announces-proposed-public-offering 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/16/sutro-biopharma-announces-encouraging-interim-phase-1-clinical-data-for-a-dose-escalation-study-of-stro-002-antibody-drug-conjugate-in-ovarian-cancer 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/17/sutro-biopharma-to-host-conference-call-on-april-27-2020-to-provide-clinical-update-on-its-stro-002-antibody-drug-conjugate 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/18/sutro-biopharma-to-present-updated-clinical-data-for-its-stro-002-antibody-drug-conjugate-at-the-aacr-virtual-annual-meeting-on-april-27-2020 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/19/sutro-biopharma-reports-full-year-2019-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/20/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/21/sutro-biopharma-to-present-innovative-cancer-therapy-approach-using-precise-tumor-targeted-immunostimulants-at-world-adc-london 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/22/sutro-biopharma-to-present-at-the-cowen-and-company-40th-annual-health-care-conference 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/23/sutro-biopharma-expands-senior-management-team-with-the-appointments-of-vice-president-of-immunobiology-and-vice-president-of-business-development 2020-08-14T18:28:29-04:00 https://ir.sutrobio.com/press-releases/detail/24/sutro-biopharma-to-present-at-38th-annual-j-p-morgan-healthcare-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/25/sutro-biopharma-appoints-james-panek-to-board-of-directors 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/26/sutro-biopharma-to-participate-in-the-31st-annual-piper-jaffray-healthcare-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/27/sutro-biopharma-to-present-at-the-stifel-2019-healthcare-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/28/sutro-biopharma-reports-third-quarter-2019-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/29/sutro-biopharma-presents-encouraging-preliminary-clinical-data-in-ongoing-phase-i-study-for-stro-002-antibody-drug-conjugate-in-patients-with-advanced-ovarian-cancer 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/30/sutro-biopharma-announces-presentation-of-stro-002-for-the-potential-treatment-of-ovarian-and-endometrial-cancer-at-the-2019-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/31/sutro-biopharma-to-receive-milestone-payment-for-novel-bispecific-antibody-drug-conjugate-targeting-solid-tumors 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/32/sutro-biopharma-to-present-at-the-h-c-wainwright-21st-annual-healthcare-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/33/sutro-biopharma-reports-second-quarter-2019-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/34/sutro-biopharma-to-present-at-the-2019-wedbush-pacgrow-healthcare-conference 2020-08-14T18:28:30-04:00 https://ir.sutrobio.com/press-releases/detail/35/sutro-biopharma-appoints-biopharma-veteran-connie-matsui-as-board-chair 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/36/sutro-biopharma-to-present-at-the-jmp-securities-life-sciences-conference 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/37/sutro-biopharma-announces-encouraging-interim-phase-1-safety-data-on-a-potential-first-in-class-antibody-drug-conjugate-stro-001-for-the-treatment-of-b-cell-malignancies-at-the-european-hematology-association-congress 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/38/sutro-biopharma-announces-presentation-at-the-2019-european-hematology-association-congress 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/39/sutro-biopharma-reports-first-quarter-2019-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/40/sutro-biopharma-to-present-at-the-18th-annual-needham-healthcare-conference 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/41/sutro-biopharma-reports-full-year-2018-financial-results-and-recent-business-highlights-and-developments 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/42/sutro-biopharma-initiates-phase-i-clinical-trial-of-stro-002-for-the-treatment-of-ovarian-and-endometrial-cancers 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/43/sutro-biopharma-to-present-at-the-cowen-and-company-39th-annual-health-care-conference 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/44/sutro-biopharma-expands-leadership-team-with-appointment-of-vice-president-of-chemistry 2020-08-14T18:28:31-04:00 https://ir.sutrobio.com/press-releases/detail/45/sutro-to-present-at-37th-annual-j-p-morgan-healthcare-conference 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/46/sutro-achieves-10-million-milestone-payment-from-celgene 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/47/sutro-to-participate-in-the-30th-annual-piper-jaffray-healthcare-conference 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/48/sutro-biopharma-reports-third-quarter-2018-financial-results 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/49/sutro-announces-ind-submission-and-conclusion-of-30-day-review-period-for-stro-002-an-antibody-drug-conjugate-adc-targeting-anti-folate-receptor--for-treatment-of-ovarian-and-endometrial-cancer 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/50/sutro-appoints-industry-veteran-shalini-sharp-to-board-of-directors 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/51/sutros-stro-001-receives-u-s-fda-orphan-drug-designation-for-treatment-of-multiple-myeloma 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/52/sutro-biopharma-announces-85-0-million-initial-public-offering 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/53/sutro-taps-worsley-as-chief-business-officer-names-fitzpatrick-as-people-and-communications-chief 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/54/sutro-and-the-leukemia-lymphoma-society-partner-on-lymphoma-and-multiple-myeloma-treatment 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/55/sutro-biopharma-announces-85-4-million-series-e-round 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/56/sutro-biopharma-collaborates-with-merck-to-develop-therapeutics-for-cancer-and-autoimmune-disorders 2020-08-14T18:28:32-04:00 https://ir.sutrobio.com/press-releases/detail/57/sutro-initiates-first-clinical-trial-of-cd74-targeting-adc-for-lymphoma-multiple-myeloma-treatment-the-first-of-a-new-generation-of-precisely-engineered-adcs 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/58/sutro-adc-effectively-targets-folate-receptor-alpha-in-ovarian-cancer-preclinical-research 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/59/sutro-antibody-effectively-targets-cd74-in-lymphoma-multiple-myeloma-preclinical-studies 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/60/sutro-marks-two-drug-development-milestones 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/61/sutro-celgene-to-refocus-2014-immuno-oncology-collaboration-on-four-programs 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/62/new-evidence-of-sutro-adcs-potency-in-human-tumor-xenografts 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/63/sutro-appoints-lobacki-as-director-leonard-krishnan-levy-as-advisors 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/64/sutro-adc-targeting-cd74-eradicates-b-cell-hematologic-malignancy-prolongs-survival-in-tumor-models 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/65/sutro-adc-targeting-cd74-exhibits-potent-anti-tumor-activity-in-multiple-malignant-cell-lines-and-animal-models-of-non-hodgkin-lymphoma-and-multiple-myeloma 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/66/sutro-adcs-targeting-cd74-suppress-tumors-in-multiple-malignant-cell-lines-and-animal-models-of-multiple-myeloma-and-non-hodgkin-lymphoma 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/67/sutro-marks-important-progress----receives-two-milestone-payments-from-celgene 2020-08-14T18:28:33-04:00 https://ir.sutrobio.com/press-releases/detail/68/sutro-appoints-shabbir-t-anik-chief-technical-operations-officer 2020-08-14T18:28:34-04:00 https://ir.sutrobio.com/press-releases/detail/69/sutro-expands-senior-leadership-team-with-addition-of-chief-medical-officer-and-vp-of-translational-pharmacology-and-preclinical-development 2020-08-14T18:28:34-04:00 https://ir.sutrobio.com/press-releases/detail/70/sutro-biopharma-receives-the-pantheon-2015-dina-outstanding-partner-award-by-the-california-life-sciences-association 2020-08-14T18:28:34-04:00 https://ir.sutrobio.com/press-releases/detail/71/sutro-biopharma-appoints-nicki-vasquez-ph-d-as-vp-of-alliance-and-project-management 2020-08-14T18:28:34-04:00 https://ir.sutrobio.com/press-releases/detail/72/sutro-biopharma-and-celgene-corporation-enter-multi-year-strategic-collaboration-and-option-to-acquire-agreement 2020-08-14T18:28:34-04:00 https://ir.sutrobio.com/press-releases/detail/73/fiercebiotech-names-sutro-biopharma-as-one-of-its-fierce-15-biotech-companies-of-2014 2020-08-14T18:28:35-04:00 https://ir.sutrobio.com/press-releases/detail/74/sutro-biopharma-and-merck-kgaa-of-darmstadt-germany-to-partner-on-development-of-antibody-drug-conjugates 2020-08-14T18:28:35-04:00 https://ir.sutrobio.com/press-releases/detail/75/sutro-biopharma-to-collaborate-with-university-of-california-san-francisco-ucsf-a-recombinant-antibody-network-ran-member 2020-08-14T18:28:35-04:00 https://ir.sutrobio.com/press-releases/detail/76/sutro-biopharma-to-present-at-21st-annual-future-leaders-in-the-biotech-industry-conference 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/77/sutro-biopharma-to-collaborate-with-memorial-sloan-kettering-cancer-center-to-produce-bispecific-antibodies-for-the-treatment-of-neuroblastoma 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/78/sutro-biopharma-closes-26-million-financing-expands-development-of-novel-immuno-oncology-products 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/79/sutro-biopharma-presents-dual-warhead-antibody-drug-conjugate-at-the-world-adc-summit 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/80/sutro-biopharma-appoints-edward-c-albini-as-chief-financial-officer 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/81/sutro-biopharma-to-collaborate-with-sanofi-pasteur-on-a-novel-production-approach-for-vaccine-candidates 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/82/sutro-licenses-click-chemistry-from-the-scripps-research-institute 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/83/sutro-closes-16-5-million-second-tranche-of-series-c-financing 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/84/sutro-announces-newly-formed-scientific-advisory-board 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/85/sutro-biopharma-to-present-its-biochemical-protein-synthesis-technology-at-bioproduction-conference-2011-in-berlin 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/86/study-shows-sutro-biopharmas-biochemical-protein-synthesis-technology-enables-rapid-production-and-scale-up-of-biopharmaceuticals 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/87/sutro-biopharma-forges-partnership-with-pfizer-for-discovery-development-and-commercialization-of-novel-peptide-based-therapeutics 2020-08-14T18:28:36-04:00 https://ir.sutrobio.com/press-releases/detail/88/sutro-biopharma-appoints-trevor-hallam-ph-d-as-chief-scientific-officer 2020-08-14T18:28:37-04:00 https://ir.sutrobio.com/press-releases/detail/89/sutro-biopharma-secures-36-5-million-in-series-c-financing 2020-08-14T18:28:37-04:00 https://ir.sutrobio.com/press-releases/detail/90/sutro-biopharma-announces-additions-to-board-of-directors-and-senior-management-team 2020-08-14T18:28:37-04:00 https://ir.sutrobio.com/press-releases/detail/91/sutro-biopharma-adds-to-extensive-ip-portfolio-with-two-newly-issued-patents-and-two-patent-grant-notices 2020-08-14T18:28:37-04:00 https://ir.sutrobio.com/press-releases/detail/92/william-j-newell-named-chief-executive-officer-of-sutro-biopharma 2020-08-14T18:28:37-04:00 https://ir.sutrobio.com/events-presentations/detail/20260310-the-citizens-life-sciences-conference-2026 2026-02-25T08:31:17-05:00 https://ir.sutrobio.com/events-presentations/detail/20260304-td-cowen-46th-annual-health-care-conference 2026-02-25T08:31:10-05:00 https://ir.sutrobio.com/events-presentations/detail/20260115-44th-annual-jp-morgan-healthcare-conference 2026-01-15T14:15:04-05:00 https://ir.sutrobio.com/events-presentations/detail/20251203-37th-annual-piper-sandler-healthcare-conference 2025-11-06T16:33:39-05:00 https://ir.sutrobio.com/events-presentations/detail/20251112-sutro-rd-day 2025-11-12T10:00:48-05:00 https://ir.sutrobio.com/events-presentations/detail/20251108-society-for-immunotherapy-of-cancer-sitc-2025-annual-meeting 2025-11-19T11:57:36-05:00 https://ir.sutrobio.com/events-presentations/detail/20251103-16th-annual-world-adc-conference 2025-12-23T16:35:17-05:00 https://ir.sutrobio.com/financials/sec-filings/content/9999999995-26-001050/primary_doc.html 2026-04-02T06:07:16-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-138220/d115714d424b3.htm 2026-04-01T17:19:16-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-120004/d115714ds3.htm 2026-03-23T17:25:09-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-119971/stro-20260323.htm 2026-03-23T17:11:13-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-119873/stro-20251231.htm 2026-03-23T16:47:28-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-119844/stro-20260323.htm 2026-03-23T16:33:22-04:00 https://ir.sutrobio.com/financials/sec-filings/content/0002063633-26-000003/form4-03062026_090355.html 2026-03-06T16:27:38-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001872398-26-000003/form4-03062026_090306.html 2026-03-06T16:21:42-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0002063633-26-000002/form4-03032026_110346.html 2026-03-03T19:00:56-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001992979-26-000002/form4-03032026_110346.html 2026-03-03T18:58:09-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001761333-26-000002/form4-03032026_110348.html 2026-03-03T18:53:10-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001872398-26-000002/form4-03032026_110347.html 2026-03-03T18:49:56-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0000921895-26-000502/primary_doc.html 2026-02-18T19:49:57-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0000919574-26-000954/primary_doc.html 2026-02-13T16:51:01-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0000919574-26-000953/primary_doc.html 2026-02-13T16:50:35-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-044934/d52363d8k.htm 2026-02-10T17:17:43-05:00 https://ir.sutrobio.com/financials/sec-filings/content/0001193125-26-044923/d72308d424b5.htm 2026-02-10T17:12:43-05:00 https://ir.sutrobio.com/privacy-policy https://ir.sutrobio.com/disclaimer https://ir.sutrobio.com/sitemap